Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free ORGS Stock Alerts

Orgenesis (ORGS) Competitors

Orgenesis logo
$0.59 0.00 (0.00%)
As of 05/22/2026 09:35 AM Eastern
Compare

ORGS vs. HEPA, WINT, PTIX, ASBP, and CMND

Should you buy Orgenesis stock or one of its competitors? MarketBeat compares Orgenesis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orgenesis include Hepion Pharmaceuticals (HEPA), Windtree Therapeutics (WINT), Atrinsic (PTIX), Aspire Biopharma (ASBP), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical products" industry.

How does Orgenesis compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
Orgenesis Neutral

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hepion Pharmaceuticals has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Orgenesis$662K4.61-$55.36M-$11.51N/A

Hepion Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Orgenesis -3,827.81%N/A -130.18%

Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market.

Summary

Orgenesis beats Hepion Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Orgenesis compare to Windtree Therapeutics?

Windtree Therapeutics (NASDAQ:WINT) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Windtree Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Orgenesis Neutral

Windtree Therapeutics has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Orgenesis$662K4.61-$55.36M-$11.51N/A

Windtree Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Orgenesis -3,827.81%N/A -130.18%

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Windtree Therapeutics beats Orgenesis on 6 of the 10 factors compared between the two stocks.

How does Orgenesis compare to Atrinsic?

Atrinsic (NASDAQ:PTIX) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Atrinsic has higher earnings, but lower revenue than Orgenesis. Atrinsic is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrinsicN/AN/A-$5.53M-$3.45N/A
Orgenesis$662K4.61-$55.36M-$11.51N/A

In the previous week, Atrinsic's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Atrinsic Neutral
Orgenesis Neutral

Atrinsic has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, suggesting that its stock price is 206% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrinsic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Atrinsic has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
AtrinsicN/A N/A -379.72%
Orgenesis -3,827.81%N/A -130.18%

Summary

Atrinsic and Orgenesis tied by winning 5 of the 10 factors compared between the two stocks.

How does Orgenesis compare to Aspire Biopharma?

Orgenesis (NASDAQ:ORGS) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Aspire Biopharma has lower revenue, but higher earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$662K4.61-$55.36M-$11.51N/A
Aspire Biopharma$10K703.30-$24.48M-$116.67N/A

Aspire Biopharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Orgenesis-3,827.81% N/A -130.18%
Aspire Biopharma N/A N/A -398.04%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aspire Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 1.9% of Orgenesis shares are held by insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Orgenesis has a beta of 3.06, indicating that its stock price is 206% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Aspire Biopharma'saverage media sentiment score.

Company Overall Sentiment
Orgenesis Neutral
Aspire Biopharma Neutral

Summary

Aspire Biopharma beats Orgenesis on 6 of the 11 factors compared between the two stocks.

How does Orgenesis compare to Clearmind Medicine?

Clearmind Medicine (NASDAQ:CMND) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Clearmind Medicine has higher earnings, but lower revenue than Orgenesis. Clearmind Medicine is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A
Orgenesis$662K4.61-$55.36M-$11.51N/A

In the previous week, Clearmind Medicine had 8 more articles in the media than Orgenesis. MarketBeat recorded 8 mentions for Clearmind Medicine and 0 mentions for Orgenesis. Clearmind Medicine's average media sentiment score of 0.24 beat Orgenesis' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Clearmind Medicine Neutral
Orgenesis Neutral

Clearmind Medicine has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, indicating that its stock price is 206% more volatile than the broader market.

Clearmind Medicine has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
Orgenesis -3,827.81%N/A -130.18%

Summary

Clearmind Medicine and Orgenesis tied by winning 6 of the 12 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGS vs. The Competition

Export
MetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.05M$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio-0.051.4621.2225.66
Price / Sales4.61119.63562.2886.31
Price / CashN/A20.0743.4956.67
Price / Book-0.097.5910.317.14
Net Income-$55.36M-$3.64M$3.57B$335.98M
7 Day Performance31.11%3.01%6.43%4.15%
1 Month Performance2.61%76.62%3.57%2.54%
1 Year Performance-68.95%126.61%34.07%35.06%

Orgenesis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGS
Orgenesis
N/A$0.59
flat		N/A-68.9%$3.05M$662KN/A150
HEPA
Hepion Pharmaceuticals
N/A$0.08
+15.7%		N/A+14.9%$943KN/AN/A20
WINT
Windtree Therapeutics
N/A$0.02
+6.4%		N/A-98.2%$895KN/AN/A30
PTIX
Atrinsic
N/A$0.49
+1.2%		N/A-87.0%$887KN/AN/A2
ASBP
Aspire Biopharma
0.1547 of 5 stars		$5.30
+2.5%		N/AN/A$860K$10KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ORGS) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel